Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
HIV/AIDS Department and Global Hepatitis Programme, World Health Organization, Geneva, Switzerland.
J Int AIDS Soc. 2020 Jun;23 Suppl 2(Suppl 2):e25530. doi: 10.1002/jia2.25530.
Few studies have systematically described population-level differences comparing men and women across the continuum of routine HIV care. This study quantifies differentials in HIV care, treatment and mortality outcomes for men and women over time in South Africa.
We analysed population-wide linked anonymized data, including vital registration linkage, for the Western Cape Province, from the time of first CD4 count. Three antiretroviral therapy guideline eligibility periods were defined: 1 January 2008 to 31 July 2011 (CD4 cell count <200 cells/µL), 1 August 2011 to 31 December 2014 (<350 cells/µL), 1 January 2015 to 31 August 2016 (<500 cells/µL). We estimated care uptake based on service attendance, and modelled associations for men and women with ART initiation and overall, pre-ART and ART mortality. Separate Cox proportional hazard models were built for each outcome and eligibility period, adjusted for tuberculosis, pregnancy, CD4 count and age.
Adult men made up 49% of the population and constituted 37% of those living with HIV. In 2009, 46% of men living with HIV attended health services, rising to 67% by 2015 compared to 54% and 77% of women respectively. Men contributed <35% of all CD4 cell counts over 10 years and presented with more advanced disease (39% of all first presentation CD4 cell counts from men were <200 cells/µL compared to 25% in women). ART access was lower in men compared to women (AHR 0.79 (0.77 to 0.80) summarized for Period 2) over the entire study). Mortality was greater in men irrespective of ART (AHR 1.08 (1.01 to 1.16) Period 3) and after ART start (AHR 1.15 (1.05 to 1.20) Period 3) with mortality differences decreasing over time.
Compared to women, men presented with more advanced disease, were less likely to attend health care services annually, were less likely to initiate ART and had higher mortality overall and while receiving ART care. People living with HIV were more likely to initiate ART if they had acute reasons to access healthcare beyond HIV, such as being pregnant or being co-infected with tuberculosis. Our findings point to missed opportunities for improving access to and outcomes from interventions for men along the entire HIV cascade.
很少有研究系统地描述了在常规 HIV 护理连续体中,男性和女性之间的人群水平差异。本研究量化了南非男性和女性在不同时间点的 HIV 护理、治疗和死亡率结果的差异。
我们分析了包括西开普省从首次 CD4 计数开始的生命登记链接在内的全人群链接匿名数据。定义了三个抗逆转录病毒治疗指南资格期:2008 年 1 月 1 日至 2011 年 7 月 31 日(CD4 细胞计数<200 个/µL)、2011 年 8 月 1 日至 2014 年 12 月 31 日(<350 个/µL)、2015 年 1 月 1 日至 2016 年 8 月 31 日(<500 个/µL)。我们根据服务就诊情况估计护理利用率,并对接受 ART 启动和总体、ART 前和 ART 死亡率的男性和女性进行建模关联。为每个结局和资格期分别建立了单独的 Cox 比例风险模型,调整了结核病、妊娠、CD4 计数和年龄。
成年男性占人口的 49%,占 HIV 感染者的 37%。2009 年,46%的 HIV 感染者就诊,到 2015 年上升到 67%,而女性分别为 54%和 77%。男性在 10 年内仅占所有 CD4 细胞计数的<35%,且表现出更晚期的疾病(39%的首次 CD4 细胞计数来自男性<200 个/µL,而女性为 25%)。与女性相比,男性接受 ART 的机会较低(第 2 期的 AHR 为 0.79(0.77 至 0.80))。在整个研究中)。无论是否接受 ART,男性的死亡率均较高(第 3 期的 AHR 为 1.08(1.01 至 1.16)),并且在开始接受 ART 后(第 3 期的 AHR 为 1.15(1.05 至 1.20)),死亡率差异随时间逐渐降低。
与女性相比,男性表现出更晚期的疾病,更不可能每年就诊,更不可能开始接受 ART,并且总体死亡率更高,同时接受 ART 护理。如果 HIV 感染者有除 HIV 以外的急性医疗需求,例如怀孕或同时感染结核病,他们更有可能开始接受 ART。我们的研究结果表明,男性在整个 HIV 连续体中,在获得和改善干预措施的机会方面存在错失。